Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)- transfected neuroblastoma Neuro-2a cells

Journal of Immunology

Volumn 162, Issue 12, 1999, Pages 7350-7357

  Shimizu, Motomu ^a   Fontana, Adriano ^b   Takeda, Yasutaka ^c   Yagita, Hideki ^d   Yoshimoto, Takayuki ^d   Matsuzawa, Akio ^d  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNITY; INFLAMMATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT REJECTION; GRANULOCYTES; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED MRL LPR; MICE, MUTANT STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033564343     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Yonehara, S., A. Ishi, and M. Yonehara. 1989. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1747.
2. Trauth, B. C., C. Klas, A. M. J. Peters, S. Matzku, P. Möller, W. Falk, K.-M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301.
3. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169.
4. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16:39.
5. Nagata, S. 1996. Fas-induced apoptosis, and diseases caused by its abnormality. Genes Cells 1:873.
6. Watanabe-Fukunaga, R., C. I. Brannan, N. Itoh, S. Yonehara, N. G. Copeland, N. A. Jenkins, and S. Nagata, 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1274.
7. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
8. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson, 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189.
9. Stuart, P. M., T. S. Griffith, N. Usui, J. Pepose, X. Yu, and T. A. Ferguson. 1977. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396.
10. Hunt, J. S., D. Vassmer, T. A. Ferguson, and L. Miller. 1997. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol. 158:4122.
11. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109.
12. Zhang, H., Y. Yang, J. L. Horton, E. B. Samoilova, T. A. Judge, L. A. Turka, J. M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100:1951.
13. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94:3943.
14. Kang, S.-M., A. Hofmann, D. Le, M. L. Springer, P. G. Stock, and H. M. Blau. 1997. Immune response and myoblasts that express Fas ligand. Science 278: 1322.
15. Kang, S.-M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1977. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738.
16. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Shreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
17. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
18. Strand, S., W. J. Hofmann, H. Hug, M. Müller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361.
19. Villunger, A., A. Egle, I. Marschitz, M. Kos, G. Bock, H. Ludwig, S. Geley, R. Kofler, and R. Greil. 1997. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 90:12.
20. Bamberger, A. M., H. M. Schulte, I. Thuneke, I. Erdmann, C. M. Bamberger, and S. L. ASA. 1997. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J. Clin. Endocrinol. Metab. 82:3173.
21. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp, D.R. Green, and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007.
22. Saas, P., P. R. Walker, M. Hahne, A. L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
23. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420.
24. Green, D. R., and C. F. Ware. 1997. Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA 94:5986.
25. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579.
26. Ungefroren, H., M. Voss, M. Jansen, C. Roeder, D. Henne-Bruns, B. Kremer, and H. Kalthoff. 1998. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 58:1741.
27. Husain, N., E. A. Chiocca, N. Rainov, D. N. Louis, and N. T. Zervas. 1998. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 95:287.
28. Gratas, C., Y. Tohma, C. Barnas, P. Taniere, P. Hainaut, and H. Ohgaki. 1998. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 58:2057.
29. Bennett, M. W., J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669.
30. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
31. Arai, H., D. Gordon, E. G. Nabel, and G. J. Nabel. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94:13862.
32. Katzenstein, H. M., and S. L. Cohn 1998. Advances in the diagnosis and treatment of neuroblastoma. Curr. Opin. Oncol. 10:43.
33. Rensing-Ehl, A., K. Frei, R. Flury, B. Matiba, S. M. Mariani, M. Weller, P. Aebischer, P. H. Krammer, and A Fontana. 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25:2253.
34. Shimizu, M., T. Yoshimoto, S. Nagata, and A. Matsuzawa. 1996. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem. Biophys. Res. Commun. 228:375.
35. Klebe, R. J., and F. H. Ruddle. 1969. Neuroblastoma: cell culture analysis of a differentiating stem cell system. J. Cell Biol. 43:69a.
36. Kayagaki, N., N. Yamaguchi, F. Nagao, S. Matsuo, H. Maeda, K. Okumura, and H. Yagita. 1997. Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA 94:3914.
37. Fleming, T. J., M. L. Fleming, and T. R. Malek. 1993. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151:2399.
38. Springer, T., G. Galfré, D. S. Secher, and C. Milstein. 1979. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur. J. Immunol. 9:301.
39. Abreu-Martin, M. T., A. Vidrich, D. H. Lynch, and S. R. Targan. 1995. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155:4147.
40. Seino, K., K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484.
41. Cassatella, M. A., S. Gasperini, and M. P. Russo. 1997. Cytokine expression and release by neutrophils. Ann. NY Acad. Sci. 832:233.
42. Colombo, M. P., L. Lombardi, A. Stoppacciaro, C. Melani, M. Parenza, B. Bottazzi, and G. Parmiani. 1992. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: neutrophils discriminate between G-CSF-producing and G-SCF-nonproducing tumor cells. J. Immunol. 149:113.
43. Pericle, F., R. A. Kirken, P. K. Epling-Burnette, D. K. Blanchard, and J. Y. Djeu. 1996. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int. J. Cancer. 66:367.
44. Midorikawa, Y., T. Yamashita, and F. Sendo. 1990. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res. 50:6243.
45. Musiani, P., A. Allione, A. Modica, P. L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Forni, and A. Modesti. 1996. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α. Lab. Invest. 74:146.
46. +) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody. Int. J. Cancer 54:131.
47. Mackensen, A., A. Lindemann, and R. Mertelsmann. 1997. Immunostimulatory cytokines in somatic cells and gene therapy of cancer. Cytokine Growth Factor Rev. 8:119.
48. Weller, M., K. Frei, P. Groscurth, P. H. Krammer, Y. Yonekawa, and A. Fontana. 1994. Anti-Fas/Apo-1 antibody-mediated apoptosis of cultured human glioma cells: induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94: 954.